Drugs in R & D

, Volume 4, Issue 6, pp 389–394 | Cite as


SC 54684A, Xemlofiban
Adis R&D Profile


Platelet Aggregation Stent Placement Abciximab Urgent Revascularisation Sibrafiban 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 91: 403–410, 15 Jan 1995PubMedCrossRefGoogle Scholar
  2. 2.
    Milton MN, Szafon T, Aboayge E. Biliary and renal excretion of SC-54701 in the dog. 7th North American ISSX Meeting 10: 274, 20 Oct 1996Google Scholar
  3. 3.
    Szalony JA, Haas NF, Salyers AK, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 91: 411–416, 15 Jan 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Higgins G. Three points of attack in fight against restenosis. Inpharma 983: 3–4, 22 April 1995Google Scholar
  5. 5.
    Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 96: 1117–1121, 19 Aug 1997PubMedCrossRefGoogle Scholar
  6. 6.
    Timmis SBH, Gregory ML, Kleiman JH, et al. Influence of oral glycoprotein IIb/IIIa blockade on bleeding and cardiovascular events in patients undergoing coronary bypass surgery. Circulation 100 (Suppl.): 153, 2 Nov 1999CrossRefGoogle Scholar
  7. 7.
    Umemura K, Nishiyama H, Kikuchi S. Inhibitory effect of GP IIb/IIIa inhibitor, SC-54684A on intima thickening in the guinea pig femoral artery. Japanese Journal of Pharmacology 67 (Suppl. I): 113, 1995Google Scholar
  8. 8.
    Umemura K, Nishiyama H, Kikuchi S, et al. Inhibitory effect of a novel orally active GPIIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery. Thrombosis and Haemostasis 76: 799–806, Nov 1996PubMedGoogle Scholar
  9. 9.
    Frederick LG, Suleymanov OD, King LW, et al. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation 93: 129–134, 1 Jan 1996PubMedCrossRefGoogle Scholar
  10. 10.
    Kottke-Marchant K, Simpfendorfer C, Lowrie M. Sustained but variable inhibition of platelet aggregation with xemlofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 92 (Suppl. I): 488, 15 Oct 1995Google Scholar
  11. 11.
    Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential doseresponse to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation 94: 906–910, 01 Sep 1996PubMedCrossRefGoogle Scholar
  12. 12.
    Kereiakes DJ, Kleiman NS, Runyon JP, et al. Sustained platelet GP IIb/IIIa blockade with oral xemilofiban: pharmacodynamics and clinical outcomes in 103 patients. Circulation 94 (Suppl.): 256–257, 15 Oct 1996CrossRefGoogle Scholar
  13. 13.
    Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 96: 76–81, 1 Jul 1997PubMedCrossRefGoogle Scholar
  14. 14.
    Kereiakes DJ, Ferguson JJ, Masud AZ. Sustained platelet Gp Iib/IIIa blockade with oral xemilofiban: final results of the ORBIT Trial. Circulation 96 (Suppl.): 385, 21 Oct 1997CrossRefGoogle Scholar
  15. 15.
    Frederick LG, Suleymanov OD, Szalony JA. Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. Circulation 98: 813–820, 25 Aug 1998PubMedCrossRefGoogle Scholar
  16. 16.
    Badimon JJ, Meyer B, Feigen LP, et al. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. European Journal of Clinical Investigation 27: 568–574, Jul 1997PubMedCrossRefGoogle Scholar
  17. 17.
    Kleiman NS. Preliminary results of the xemilofiban phase-II ORBIT study in patients undergoing percutaneous coronary revascularization. XIXth Congress of the European Society of Cardiology: Oral Glycoprotein IIb/IIa Antagonists: 8, 26 Aug 1997Google Scholar
  18. 18.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 98: 1268–1278, 29 Sep 1998PubMedCrossRefGoogle Scholar
  19. 19.
    O’Neill WW. The evaluation of xemilofiban in controlling thrombotic events (EXCITE) trial: 30-day and six-month results. Journal of the American College of Cardiology 33 (Suppl. A): Feb 1999Google Scholar
  20. 20.
    Chew DP, Bhatt DL, Topol EJ. Increased mortality with oral glycoprotein IIb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIb/IIIa trials. Journal of the American College of Cardiology 35 (Suppl. A): 393, Feb 2000Google Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations